Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0RHRIK
ADC Name
PSG4R AP25
Synonyms
PSG4R-AP25
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Colon cancer [ICD11:2B90]
Investigative
Antibody Name
Anti-ITGA5 mAb Fc
  Antibody Info 
Antigen Name
Integrin alpha-5 (ITGA5)
  Antigen Info 
Payload Name
AP25
  Payload Info 
Therapeutic Target
Integrin alpha-5 (ITGA5)
  Target Info 
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 38
%
HCT 116 cells
Colon carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 38.00% (Day 15) Positive ITGA5 expression (ITGA5 +++/++)
Method Description
Sixty nude mice with good growth condition and good homogeneity of tumor size were selected when the tumors grew to about 80-100 mm3. The mice in each group were intravenously administrated with drugs at 0.2 mL/20 g body weight. .
In Vivo Model HCT-116 CDX model
In Vitro Model Colon carcinoma HCT 116 cells CVCL_0291
References
Ref 1 Anti-Tumor Activity and Pharmacokinetics of AP25-Fc Fusion Protein. Int J Med Sci. 2019 Jun 10;16(7):1032-1041. doi: 10.7150/ijms.34365. eCollection 2019.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.